Vlastimil Ščudla

775 total citations
42 papers, 265 citations indexed

About

Vlastimil Ščudla is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Vlastimil Ščudla has authored 42 papers receiving a total of 265 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 22 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Vlastimil Ščudla's work include Multiple Myeloma Research and Treatments (32 papers), Peptidase Inhibition and Analysis (11 papers) and Protein Degradation and Inhibitors (8 papers). Vlastimil Ščudla is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Peptidase Inhibition and Analysis (11 papers) and Protein Degradation and Inhibitors (8 papers). Vlastimil Ščudla collaborates with scholars based in Czechia, Slovakia and United States. Vlastimil Ščudla's co-authors include Tomáš Pika, Jiří Minařík, Jaroslav Bačovský, Roman Hájek, Vladimír Maisnar, Kateřina Langová, Evžen Gregora, Marie Jarošová, Tomáš Büchler and Jiří Vymětal and has published in prestigious journals such as Blood, Oncotarget and Bone Marrow Transplantation.

In The Last Decade

Vlastimil Ščudla

39 papers receiving 258 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vlastimil Ščudla Czechia 11 177 144 117 43 17 42 265
Gergely Varga Hungary 10 154 0.9× 121 0.8× 79 0.7× 51 1.2× 23 1.4× 40 239
Edgar Braendle United States 5 100 0.6× 179 1.2× 160 1.4× 17 0.4× 17 1.0× 10 321
Nazir Jamal Canada 6 74 0.4× 92 0.6× 101 0.9× 38 0.9× 19 1.1× 9 270
Pınar Tarkun Türkiye 9 114 0.6× 126 0.9× 82 0.7× 45 1.0× 15 0.9× 30 309
Ali‐Reza Golshayan United States 7 81 0.5× 172 1.2× 45 0.4× 45 1.0× 12 0.7× 9 313
José Antonio Queizán Spain 7 103 0.6× 74 0.5× 58 0.5× 48 1.1× 26 1.5× 13 169
Weiying Gu China 10 58 0.3× 95 0.7× 76 0.6× 28 0.7× 55 3.2× 35 247
Miriam Hobbs United States 7 139 0.8× 129 0.9× 80 0.7× 75 1.7× 15 0.9× 26 225
Carlos Hader United States 5 215 1.2× 67 0.5× 53 0.5× 114 2.7× 28 1.6× 7 299
John Townsend United Kingdom 3 125 0.7× 188 1.3× 53 0.5× 65 1.5× 25 1.5× 3 294

Countries citing papers authored by Vlastimil Ščudla

Since Specialization
Citations

This map shows the geographic impact of Vlastimil Ščudla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vlastimil Ščudla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vlastimil Ščudla more than expected).

Fields of papers citing papers by Vlastimil Ščudla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vlastimil Ščudla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vlastimil Ščudla. The network helps show where Vlastimil Ščudla may publish in the future.

Co-authorship network of co-authors of Vlastimil Ščudla

This figure shows the co-authorship network connecting the top 25 collaborators of Vlastimil Ščudla. A scholar is included among the top collaborators of Vlastimil Ščudla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vlastimil Ščudla. Vlastimil Ščudla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ščudla, Vlastimil & Pavel Hořák. (2023). Differential diagnosis of increased Erythrocyte Sedimentation rate. Vnitřní lékařství. 69(1). 48–56. 1 indexed citations
2.
Minařík, Jiří, Tomáš Jelı́nek, Alexandra Jungová, et al.. (2018). Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes. Blood. 132(Supplement 1). 1959–1959. 4 indexed citations
3.
Pika, Tomáš, et al.. (2018). Cardiac amyloidosis: from clinical suspicion to morphological diagnosis. Pathology. 50(3). 261–268. 21 indexed citations
4.
Minařík, Jiří, et al.. (2017). CD38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapy. European Journal Of Haematology. 99(2). 186–189. 14 indexed citations
5.
Minařík, Jiří, et al.. (2014). „High cut-off“ hemodialýza - nová možnost v terapii ledvinného selhání u mnohočetného myelomu. Interní medicína pro praxi. 16(5). 192–195. 1 indexed citations
6.
Minařík, Jiří, Tomáš Pika, Jaroslav Bačovský, & Vlastimil Ščudla. (2013). Kryoglobulinemická vaskulitida u nemocného s mnohočetným myelomem. Interní medicína pro praxi. 14(12). 478–480.
7.
Minařík, Jiří, M. Heřman, Tomáš Pika, et al.. (2013). Correlation of selected parameters of bone microenvironment to the extent of myeloma bone disease. European Journal of Internal Medicine. 24. e167–e167. 1 indexed citations
8.
Minařík, Jiří, et al.. (2012). Prognostic Value of Hepatocyte Growth Factor, Syndecan-1, and Osteopontin in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. The Scientific World JOURNAL. 2012. 1–6. 13 indexed citations
9.
Němec, Pavel, Zuzana Zemanová, Petr Kuglík, et al.. (2011). Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leukemia & lymphoma. 53(5). 920–927. 34 indexed citations
10.
Krejčí, Marta, Evžen Gregora, Jan Štraub, et al.. (2011). Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. Annals of Hematology. 90(12). 1441–1447. 2 indexed citations
11.
Ščudla, Vlastimil, Tomáš Pika, Marie Budı́ková, et al.. (2010). The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma. 57(2). 102–110. 8 indexed citations
12.
Minařík, Jiří, et al.. (2010). Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma. Neoplasma. 57(1). 8–14. 2 indexed citations
13.
Minařík, Jiří, et al.. (2009). Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. European Journal Of Haematology. 83(6). 528–534. 3 indexed citations
14.
Pika, Tomáš, Jiří Minařík, Marie Budı́ková, et al.. (2008). THE CORRELATION OF SERUM IMMUNOGLOBULIN FREE LIGHT CHAIN LEVELS AND SELECTED BIOLOGICAL MARKERS IN MULTIPLE MYELOMA. Biomedical Papers. 152(1). 61–64. 4 indexed citations
15.
Martínek, Arnošt, et al.. (2007). Význam hodnocení sérových hladin volných lehkých řetězců imunoglobulinů u monoklonálních gamapatií. Interní medicína pro praxi. 8(11). 502–504.
16.
Maisnar, Vladimír, Roman Hájek, Vlastimil Ščudla, et al.. (2007). High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Bone Marrow Transplantation. 41(1). 51–54. 14 indexed citations
17.
Büchler, Tomáš, Marta Krejčí, Adam Svobodník, et al.. (2005). Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. The Hematology Journal. 5(7). 559–564. 9 indexed citations
18.
Bačovský, Jaroslav, et al.. (2002). Monitoring of bone resorption and bone formation in multiple myeloma.. Biomedical Papers. 146(2). 59–61. 4 indexed citations
19.
Jarošová, Marie, et al.. (1996). Two cases of t(9;20) in multiple myeloma. Cancer Genetics and Cytogenetics. 90(2). 106–108. 1 indexed citations
20.
Ščudla, Vlastimil, et al.. (1990). Bone marrow necrosis intravitally recognized in four cases of blastic leukaemia.. PubMed. 117(6). 799–803. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gergely Varga Breakdown of academic impact, for papers by Edgar Braendle Breakdown of academic impact, for papers by Nazir Jamal Breakdown of academic impact, for papers by Pınar Tarkun Breakdown of academic impact, for papers by Ali‐Reza Golshayan Breakdown of academic impact, for papers by José Antonio Queizán Breakdown of academic impact, for papers by Weiying Gu Breakdown of academic impact, for papers by Miriam Hobbs Breakdown of academic impact, for papers by Carlos Hader Breakdown of academic impact, for papers by John Townsend
Rankless by CCL
2026